Sitneprotafib clinical trials
Also written JAB-3312.
How each study uses sitneprotafib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sitneprotafib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- JAB-3312
- 5
Studies by the year they started
5 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Allist Pharmaceuticals, Inc. (4) · Jacobio Pharmaceuticals Co., Ltd. (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test sitneprotafib.
- Mar 2027Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C MutationPhase 1/2 · Allist Pharmaceuticals, Inc.
Studies
Open first, then newest update. How each study uses sitneprotafib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C MutationRecruitingPhase 3Allist Pharmaceuticals, Inc.NCT06416410Written as JAB-3312
- Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C MutationRecruitingPhase 1/2Allist Pharmaceuticals, Inc.NCT05288205Written as JAB-3312
- A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid TumorsCompletedPhase 1Jacobio Pharmaceuticals Co., Ltd.NCT04045496Written as JAB-3312
- A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in ChinaCompletedPhase 1Allist Pharmaceuticals, Inc.NCT04121286Written as JAB-3312
- JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid TumorsCompletedPhase 1/2Allist Pharmaceuticals, Inc.NCT04720976Written as JAB-3312
Codes
What other systems call sitneprotafib · ClinicalTrials.gg INT017958
- UNII (FDA) T21N67B1V3SITNEPROTAFIBOne source FDA
- NCI Thesaurus C164218SitneprotafibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | T21N67B1V3 | SITNEPROTAFIB | One source FDA |
| NCI Thesaurus | C164218 | Sitneprotafib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.